Stoke Therapeutics (STOK) Accumulated Depreciation (2018 - 2025)

Stoke Therapeutics' Accumulated Depreciation history runs 8 years deep, the most recent figure standing at $10.1 million for Q4 2025.

• In Q4 2025, Accumulated Depreciation rose 14.67% year-over-year to $10.1 million; the TTM figure through Dec 2025 stood at $10.1 million (up 14.67% YoY), while the FY2025 annual figure was $10.1 million, up 14.67% from the prior year.
• Accumulated Depreciation was $10.1 million for Q4 2025 at Stoke Therapeutics, up from $8.8 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $10.1 million in Q4 2025 to a low of $2.7 million in Q4 2021.
• Historically, Accumulated Depreciation has averaged $6.5 million across 5 years, with a median of $6.7 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Accumulated Depreciation soared 58.57% in 2023, then advanced 14.67% in 2025.
• A 5-year view of Accumulated Depreciation shows it stood at $2.7 million in 2021, then soared by 58.1% to $4.2 million in 2022, then jumped by 58.57% to $6.7 million in 2023, then surged by 32.63% to $8.8 million in 2024, then rose by 14.67% to $10.1 million in 2025.
• The last three Accumulated Depreciation figures came in at $10.1 million (Q4 2025), $8.8 million (Q4 2024), and $6.7 million (Q4 2023), per Business Quant data.